Systemic lupus erythematosus: a case-based presentation of renal, neurologic, and hematologic emergencies

References

• Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63(3):1164–1177.
   PubMed Web of Science ®Google Scholar
• Chen S, Chen H, Liu Z, et al. Pathological spectrums and renal prognosis of severe lupus patients with rapidly progressive glomerulonephritis. Rheumatol Int. 2015;35(4):709–717.
   PubMed Web of Science ®Google Scholar
• Yu F, Wu L-H, Tan Y, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 international society of nephrology and renal pathology society system. Kidney Int. 2010;77(9):820–829.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
   PubMed Web of Science ®Google Scholar
• Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76:476–485.
   PubMed Web of Science ®Google Scholar
• Schena FP. Survey of the Italian registry of renal biopsies. frequency of the renal diseases for 7 consecutive years. The Italian group of renal immunopathology. Nephrol Dial Transplant. 1997;12(3):418–426.
   PubMed Web of Science ®Google Scholar
• Jones RB, Furuta S, Tervaert JWC, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178–1182.
   PubMed Web of Science ®Google Scholar
• Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology. 2016;55(2):252–262.
   PubMed Web of Science ®Google Scholar
• Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65(3):753–763.
   PubMedGoogle Scholar
• Grande JP. The pathogenesis of lupus nephritis. J Clin Cell Immunol. 2014;5(2):1–14.
   Google Scholar
• Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc of Nephrol. 2013;24(9):1357–1366.
   PubMed Web of Science ®Google Scholar
• Weening JJ. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15(2):241–250.
   PubMed Web of Science ®Google Scholar
• Erre GL, Bosincu L, Faedda R, et al. Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study. Rheumatol Int. 2013;34(4):535–541.
   Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797–808.
   PubMed Web of Science ®Google Scholar
• Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus. 2016;14(1):25–30.
   Google Scholar
• Wilhelmus S, Bajema IM, Bertsias GK, et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant. 2016;31(6):904–913.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340(8822):741–745.
   PubMed Web of Science ®Google Scholar
• Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–1594.
   PubMed Web of Science ®Google Scholar
• Arimura Y, Muso E, Fujimoto S, et al. Evidence-based clinical practice guidelines for rapidly progressive glomerulonephritis 2014. Clin Exp Nephrol. 2016;20(3):322–341.
   PubMed Web of Science ®Google Scholar
• Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135(4):248–257.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46(8):2121–2131.
   PubMed Web of Science ®Google Scholar
• Badsha H, Kong KO, Lian TY, et al. Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus. 2002;11(8):508–513.
   PubMed Web of Science ®Google Scholar
• Kong KO, Badsha H, Lian TY, et al. Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares. Lupus. 2004;13(3):212–213.
   PubMed Web of Science ®Google Scholar
• Steinberg AD, Decker JL. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum. 1974;17(6):923–937.
   PubMed Web of Science ®Google Scholar
• Gourley MF, Austin HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125(7):549–557.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61–64.
   PubMed Web of Science ®Google Scholar
• Wofsy D, Diamond B, Houssiau FA. Commentary: crossing the Atlantic: the Euro-lupus nephritis regimen in North America. Arthritis Rheum. 2015;67(5):1144–1146.
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103–1112.
   PubMed Web of Science ®Google Scholar
• Chan T-M, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou nephrology study group. N Engl J Med. 2000;343(16):1156–1162.
   PubMed Web of Science ®Google Scholar
• Chan T-M, Tse K-C, Tang CS-O, et al. Hong Kong nephrology study group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16(4):1076–1084.
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219–2228.
   PubMed Web of Science ®Google Scholar
• Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006;70(4):732–742.
   PubMed Web of Science ®Google Scholar
• Shelp WD, Bloodworth JM, Rieselbach RE. Effect of azathioprine on renal histology and function in lupus nephritis. Arch Intern Med. 1971;128(4):566–573.
   PubMedGoogle Scholar
• Mok CC. Pro: the use of calcineurin inhibitors in the treatment of lupus nephritis. Nephrol Dial Transplant. 2016;31(10):1561–1566.
   PubMedGoogle Scholar
• Karim MY, Alba P, Cuadrado M-J, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology. 2002;41(8):876–882.
   PubMed Web of Science ®Google Scholar
• Moss KE, Isenberg DA. Comparison of renal disease severity and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone. Rheumatology. 2001;40(8):863–867.
   PubMed Web of Science ®Google Scholar
• Díaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357–364.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Díaz-Lagares C, Soto-Cardenas M-J, et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol. 2011;40(3):159–169.
   PubMed Web of Science ®Google Scholar
• McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12(7):1162–1172.
   PubMed Web of Science ®Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. 2017 American college of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 2017;69(8):1521–1537.
   PubMed Web of Science ®Google Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257–2276.
   PubMed Web of Science ®Google Scholar
• van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414–422.
   PubMed Web of Science ®Google Scholar
• Limper AH, Knox KS, Sarosi GA, et al. An official American thoracic society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96–128.
   PubMed Web of Science ®Google Scholar
• Shotan A, Widerhorn J, Hurst A, et al. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. American J Med. 1994;96(5):451–456.
   PubMed Web of Science ®Google Scholar
• Burrows RF, Burrows EA. Assessing the teratogenic potential of angiotensin-converting enzyme inhibitors in pregnancy. Aust N Z J Obstet Gynaecol. 1998;38(3):306–311.
   PubMed Web of Science ®Google Scholar
• Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443–2451.
   PubMed Web of Science ®Google Scholar
• Imbasciati E, Tincani A, Gregorini G, et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant. 2008;24(2):519–525.
   PubMed Web of Science ®Google Scholar
• Henderson JT, Whitlock EP, O’Connor E, et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. preventive services task Force. Ann Intern Med. 2014;160(10):695–703.
   PubMed Web of Science ®Google Scholar
• Tincani A, Branch W, Levy RA, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus. 2016;12(7):524–529.
   Google Scholar
• Kaplin AI, Krishnan C, Deshpande DM, et al. Diagnosis and management of acute myelopathies. Neurologist. 2005;11(1):2–18.
   PubMed Web of Science ®Google Scholar
• Li X-Y, Xiao P, Xiao H-B, et al. Myelitis in systemic lupus erythematosus frequently manifests as longitudinal and sometimes occurs at low disease activity. Lupus. 2014;23(11):1178–1186.
   PubMed Web of Science ®Google Scholar
• Gupta SS, Shankar S, Stein E, et al. Neurosarcoidosis-induced longitudinal extensive transverse myelitis. Neurol India. 2017;65(5):1131–1134.
   PubMed Web of Science ®Google Scholar
• Greenberg BM, Frohman EM. Immune-mediated myelopathies. Continuum. 2015;21(1):121–131.
   PubMedGoogle Scholar
• Birnbaum J, Petri M, Thompson R, et al. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum. 2009;60(11):3378–3387.
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074–2082.
   PubMed Web of Science ®Google Scholar
• Group TMCW. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499–505.
   PubMed Web of Science ®Google Scholar
• Rodrigues CEM, de Carvalho JF. Clinical, radiologic, and therapeutic analysis of 14 patients with transverse myelitis associated with antiphospholipid syndrome: report of 4 cases and review of the literature. Semin Arthritis Rheum. 2011;40(4):349–357.
   PubMed Web of Science ®Google Scholar
• Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, et al. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus. 2014;24(1):74–81.
   PubMed Web of Science ®Google Scholar
• Lu X, Gu Y, Wang Y, et al. Prognostic factors of lupus myelopathy. Lupus. 2008;17(4):323–328.
   PubMed Web of Science ®Google Scholar
• Kovacs B, Lafferty TL, Brent LH, et al. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000;59(2):120–124.
   PubMed Web of Science ®Google Scholar
• Harisdangkul V, Doorenbos D, Subramony SH. Lupus transverse myelopathy: better outcome with early recognition and aggressive high-dose intravenous corticosteroid pulse treatment. J Neurol. 1995;242(5):326–331.
   PubMed Web of Science ®Google Scholar
• Sakthiswary R, D’Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus. Medicine. 2014;93(16):e86–9.
   PubMed Web of Science ®Google Scholar
• Cervera R, Asherson RA. Clinical and epidemiological aspects in the antiphospholipid syndrome. Immunobiology. 2003;207(1):5–11.
   PubMed Web of Science ®Google Scholar
• Erkan D, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome: where do we stand? Arthritis Rheum. 2003;48(12):3320–3327.
   PubMedGoogle Scholar
• Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54(8):2568–2576.
   PubMed Web of Science ®Google Scholar
• Galli M. Treatment of the antiphospholipid syndrome. Autoimmun Highlights. 2013;5(1):1–7.
   PubMedGoogle Scholar
• Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346(10):752–763.
   PubMed Web of Science ®Google Scholar
• Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011–1018.
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.
   PubMed Web of Science ®Google Scholar
• Vila P, Hernández MC, López-Fernández MF, et al. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. J Thromb Haemost. 1994;72(2):209–213.
   Google Scholar
• Erkan D, Aguiar CL, Andrade D, et al. 14th International congress on antiphospholipid antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–696.
   PubMed Web of Science ®Google Scholar
• Cervera R, Rodríguez-Pintó I, Colafrancesco S, et al. 14th International congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev. 2014;13(7):699–707.
   PubMed Web of Science ®Google Scholar
• Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med. 2003;349(12):1177–1179.
   PubMed Web of Science ®Google Scholar
• Urbanus RT, Derksen R, Groot DE. PG. Platelets and the antiphospholipid syndrome. Lupus. 2008;17(10):888–894.
   PubMed Web of Science ®Google Scholar
• Kinev AV, Roubey R. Tissue factor in the antiphospholipid syndrome. Lupus. 2008;17(10):953–959.
   Web of Science ®Google Scholar
• Forastiero R, Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus. 2008;17(10):872–877.
   PubMed Web of Science ®Google Scholar
• Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013;368(11):1033–1044.
   PubMed Web of Science ®Google Scholar
• Wahl DG, Bounameaux H, de Moerloose P, et al. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med. 2000;160(13):2042–2048.
   PubMedGoogle Scholar
• Alarcón-Segovia D, Boffa M-C, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus. 2016;12(7):499–503.
   Google Scholar
• Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3(5):848–853.
   PubMed Web of Science ®Google Scholar
• Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133–1138.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57(8):1487–1495.
   PubMed Web of Science ®Google Scholar
• Vargas-Hitos JA, Ateka-Barrutia O, Sangle S, et al. Efficacy and safety of long-term low molecular weight heparin in patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70(9):1652–1654.
   PubMed Web of Science ®Google Scholar
• Dentali F, Manfredi E, Crowther M, et al. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost. 2005;3(9):2121–2123.
   PubMed Web of Science ®Google Scholar
• Cohen H, Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3(9):e426–36.
   PubMed Web of Science ®Google Scholar
• Dufrost V, Risse J, Zuily S, et al. Direct oral anticoagulants use in antiphospholipid syndrome: are these drugs an effective and safe alternative to warfarin? A systematic review of the literature. Curr Rheumatol Rep. 2016;18(12):295–298.
   Web of Science ®Google Scholar
• Kumar D, Roubey RAS. Use of rituximab in the antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12(1):40–44.
   PubMedGoogle Scholar
• Erre GL, Pardini S, Faedda R, et al. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus. 2008;17(1):50–55.
   PubMed Web of Science ®Google Scholar
• Khattri S, Zandman-Goddard G, Peeva E. B-cell directed therapies in antiphospholipid antibody syndrome — new directions based on murine and human data. Autoimmun Rev. 2012;11(10):717–722.
   PubMed Web of Science ®Google Scholar
• Erkan D, Vega J, Ramón G, et al. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. 2013;65(2):464–471.
   PubMed Web of Science ®Google Scholar
• Bakshi J, Stevens R. Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome. Lupus. 2013;22(8):865–867.
   PubMed Web of Science ®Google Scholar
• Adamson R, Sangle S, Kaul A, et al. Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin. 2008;14(6):359–360.
   Google Scholar
• Chen H, Zheng W, Su J, et al. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus–a prospective pilot study. Rheumatology. 2011;50(9):1640–1644.
   PubMed Web of Science ®Google Scholar
• Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013;27(3):495–520.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Khamashta MA, D’Cruz DP. Targeted therapy in antiphospholipid syndrome. Curr Opin Rheumatol. 2014;26(3):269–275.
   PubMed Web of Science ®Google Scholar
• Punnialingam S, Khamashta MA. Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop? Curr Rheumatol Rep. 2013;15(4):295–298.
   Web of Science ®Google Scholar
• Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, et al. Potential use of statins in the treatment of antiphospholipid syndrome. Curr Rheumatol Rep. 2011;14(1):87–94.
   Web of Science ®Google Scholar
• Statkute L. Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hematopoietic stem cell transplantation. Blood. 2005;106(8):2700–2709.
   PubMed Web of Science ®Google Scholar
• Sanz I. May you live in interesting times: challenges and opportunities in lupus research. Arthritis Rheum. 2017;69(8):1552–1559.
   Web of Science ®Google Scholar